Current price is more than the intrinsic value

Intrinsic Value

Stock has been generating better return on equity than bank FD

ROE vs FD rates

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

The updated National List of Essential Medicines includes 384 drugs across different therapies.

Sanofi, GSK Seen ‘Negatively Impacted’ By Essential Drug Price Cap

GSK would have to reduce prices for its antibiotics Ceftum and T- Bact which cumulatively cover around 15% of its sales, while Sanofi would have to reduce prices for Lantus - an opthalamic drug which has a fair share of 22 per cent of its sales.

GSK, Sanofi may have negative impact after inclusion of their drugs in Essential Medicines List 2022

The decline was largely on account of divestment of its nutraceutical business and a few key brands.

Sanofi may underperform in near term; pricing control among key risks

A trial dubbed AMEERA-5, which was testing amcenestrant on women with newly-diagnosed advanced breast cancer, was stopped early because an independent monitoring panel found no signs of it working. “All other studies of amcenestrant, including in early-stage breast cancer (AMEERA-6), will be discont…

Sanofi trial failure ends development of breast cancer treatment amcenestrant

The news on Tuesday came days after shares of GlaxoSmithKline Plc, Sanofi SA, Pfizer Inc, and Haleon Plc were hit by investor concerns about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer.

Plaintiff in first Zantac lawsuit set for trial drops case

Sanofi fell 13% on Thursday, taking its 2-day decline to 20%; GSK slid 6.9%

Sanofi, GSK and Haleon lead $40-billion rout on heartburn drug

Sanofi India Q2 Review - High Costs Suppress Margins: ICICI Securities

The company intends to pay the said dividend on or after August 22, 2022.

Sanofi India declares one-time Special Interim Dividend of Rs193 for FY22; stock slips ~2%

Sanofi India has announced a one-time special interim dividend of Rs 193 per equity share for the financial year ending December 31

This Pharma Company Declares 1930% Special Dividend; Key Details Investors Should Know

Sanofi India standalone net profit declines 32.47% in the June 2022 quarter

Sanofi India Ltd clocked volume of 1.46 lakh shares by 14:14 IST on NSE, a 27.33 times surge over two-week average daily volume of 5354 shares

Volumes soar at Sanofi India Ltd counter

Sanofi India Limited is engaged in the manufacture and sale of pharmaceutical products.

Sanofi India Ltd

Sanofi India Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Sanofi, GSK Seen ‘Negatively Impacted’ By Essential Drug Price Cap

GSK, Sanofi may have negative impact after inclusion of their drugs in Essential Medicines List 2022

Sanofi may underperform in near term; pricing control among key risks

Sanofi trial failure ends development of breast cancer treatment amcenestrant

Plaintiff in first Zantac lawsuit set for trial drops case

Sanofi, GSK and Haleon lead $40-billion rout on heartburn drug

Sanofi India Q2 Review - High Costs Suppress Margins: ICICI Securities

Sanofi India Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Sanofi, GSK Seen ‘Negatively Impacted’ By Essential Drug Price Cap

GSK, Sanofi may have negative impact after inclusion of their drugs in Essential Medicines List 2022

Sanofi may underperform in near term; pricing control among key risks

Sanofi trial failure ends development of breast cancer treatment amcenestrant

Plaintiff in first Zantac lawsuit set for trial drops case

Sanofi, GSK and Haleon lead $40-billion rout on heartburn drug

Sanofi India Q2 Review - High Costs Suppress Margins: ICICI Securities

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock